Dexcom 2025-26: Revenue $4.66B (+13%), G7 15-Day, FY26 +11-13%
FY25 revenue $4.66B (+13%); op income $912M (+52%); NI $836M (+45%); EPS $2.09 (+47%). Q4 worldwide revenue $1.26B (+13%, organic 12%); US +11%; International +18% (organic 15%). Q4 gross profit $799.8M (63.5% of revenue, vs 59.4% FY24, +410bp). G7 15-day system broadly rolled out US. International expansion ramping (France type 2 access). Stelo nutrition database + DexCom Smart Basal launched. Direct EHR integration with 160+ health systems. FY26: revenue $5.16B-$5.25B (+11-13%); GM 63-64% (+200-300bp); op margin 22-23%; adj EBITDA 30-31%.
Key takeaways
- Q4 gross margin 63.5% (+410bp YoY). This is the structural margin inflection — G7 platform efficiencies + freight + scrap rate improvements + manufacturing scale. FY26 guide of 63-64% (+200-300bp) signals continued expansion. Long-run target appears in 65-70% range.
- G7 15-day system broadly rolled out in US. Wear-time and accuracy feedback "excellent." 15-day wear duration (vs prior 10-day) reduces sensor consumption per patient and improves customer economics. Material structural change in Dexcom's product cadence.
- International revenue Q4 +18% (organic 15%). France type 2 access expansion driving acceleration. International TAM is materially larger than US over time per mgmt — currently smaller share but compounding faster. Multi-year international expansion runway.
- Adj operating margin 22-23% / Adj EBITDA 30-31% FY26 guide. Continued operating leverage on ~13% revenue growth. The cleanest medical-device platform compounding profile in CGM (continuous glucose monitoring) — similar to Abbott Libre but with G7 platform advantage.
- Buyback $-500M FY25 (vs $-750M FY24). Capital return continuing. No dividend (growth-stage device). Total debt $1.39B (-46% YoY) — significant deleveraging.
Business
DexCom, Inc. is the global leader in continuous glucose monitoring (CGM) — sensor-based devices that measure interstitial glucose continuously and transmit real-time readings to phones / pumps / health systems. The CGM market is one of the fastest-growing medical device categories, addressing the ~38M people with diabetes in the US and ~530M+ globally.
Three primary product lines + service / software ecosystem:
- G7 (10-day, 15-day) (~75% of revenue). Latest CGM platform; smaller, more accurate, longer wear. G7 15-day broadly rolled out US Q4. Lower cost per day vs G6.
- G6 (legacy) (~10%). Predecessor platform; declining mix as G7 cannibalizes.
- Stelo (Type 2 OTC + wellness) (~5%). Over-the-counter CGM for type 2 diabetics + general wellness consumers (no prescription required). New TAM expansion. Stelo nutrition database launched FY25.
- Software / Apps / EHR Integration (~10%). My DexCom Account, DexCom Smart Basal launch (insulin dosing recommendation), Direct EHR integration with 160+ health systems. App redesign planned.
Strategic moves FY25:
- G7 15-day broadly rolled out US (Q4)
- DexCom Smart Basal launched (insulin dosing recommendation)
- Stelo nutrition database launched (OTC + wellness)
- My DexCom Account customer experience improvements
- Direct EHR integration scaled to 160+ health systems
- France type 2 access expansion (international)
- Tailored CGM products for international markets
- New patch technology for better sensor survival
- Plan to invest in Ireland manufacturing facility
- $-500M buyback FY25 (vs $-750M FY24, -33%)
- App redesign planned for FY26
FY25 financial performance
| Metric (FY) | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue ($B) | 2.91 | 3.62 | 4.03 | 4.66 |
| Revenue YoY | n/a | +25% | +12% | +16% (reported); +13% Q4 |
| Op income ($M) | 391 | 598 | 600 | 912 |
| Op margin | 13.4% | 16.5% | 14.9% | 19.6% |
| Net income ($M) | 341 | 542 | 576 | 836 |
| Diluted EPS ($) | 0.80 | 1.30 | 1.42 | 2.09 |
| Gross margin | 64.7% | 63.2% | 60.5% | 60.1% (FY) / 63.5% (Q4) |
| FCF ($M) | 305 | 512 | 631 | 1,077 |
| Capex ($M) | -365 | -237 | -359 | -364 |
| Total debt ($B) | 2.15 | 2.59 | 2.59 | 1.39 |
| Buyback ($M) | -558 | -689 | -750 | -500 |
The earnings progression: revenue 4-yr CAGR ~17%; op margin 13.4% → 19.6% (+620bp); EPS $0.80 → $2.09 (+161% over 3 yrs). Q4 gross margin 63.5% (+410bp YoY) is the cleanest forward indicator — full-year FY26 GM guide of 63-64% reflects continued expansion.
FCF $1.08B (+71% YoY) — cash flow strength inflecting as G7 platform economics scale.
Total debt $1.39B (-46% YoY, $-1.20B reduction) — substantial deleveraging. The combination of FCF inflection + $-500M buyback + debt reduction reflects strong capital efficiency.
Capital allocation
- Capex $-364M FY25 (~8% of revenue). Includes Ireland manufacturing facility investment. FY26 continues Ireland investment.
- Dividends $0 (growth-stage device; no dividend).
- Buybacks $-500M FY25 (-33% vs $-750M FY24). Continued capital return; pace moderated.
- Debt $1.39B (-46% YoY). Material deleveraging.
- FCF $1.08B (+71% YoY).
- Cash Strong — supports continued investment + capital return + manufacturing buildout.
FY26 outlook (per Q4 2025 call, 2026-02-12)
| FY26 framework | Detail |
|---|---|
| Revenue | $5.16B to $5.25B (+11% to +13%) |
| Non-GAAP gross profit margin | 63% to 64% (+200-300bp) |
| Operating profit margin | ~22% to 23% |
| Adjusted EBITDA margin | ~30% to 31% |
| Capex | Continued Ireland manufacturing investment |
| Sales | Continued investment |
| Innovation | Continued R&D investment |
| New products | Plan to add new products in 2026 |
The 11-13% revenue growth + 200-300bp gross margin expansion + 22-23% op margin + 30-31% adj EBITDA margin = continued multi-year compounding. The core lever is G7 15-day mix shift + international scaling + Stelo TAM expansion.
Key risks
Coverage landscape changes. Q4 mgmt explicit risk. CMS + private payer coverage policies for CGM affect reimbursement + access. Tightening coverage (e.g., type 2 step-edit requirements) could compress US CGM volume growth.
Competitive dynamics. Abbott Libre (FreeStyle Libre 3) is the primary CGM competitor with significant scale. Medtronic Guardian + Senseonics implantable CGM also competing. Abbott has historically had lower-cost positioning while DexCom has had accuracy / G7 platform advantage. Pricing dynamics could compress.
Supply chain issues. Q4 mgmt called out as risk. CGM manufacturing is complex (sensors, transmitters, electronics). Supply disruptions (semiconductor, polymer, freight) could affect production cadence + margin.
International market pricing. International expansion (France, Germany, etc.) requires accepting lower per-patient pricing in many markets. International margin lower than US — international mix shift compresses overall margin even as revenue grows.
G7 15-day adoption pace. Broad rollout US Q4. Patient acceptance + insurance coverage + provider workflow integration all matter. Slower-than-expected adoption could compress US revenue growth.
Stelo OTC dynamics. OTC + wellness consumer segment is a new market for DexCom. Distribution + marketing economics + consumer behavior + retention dynamics all unproven at scale. Stelo could underperform expectations.
GLP-1 drug impact (uncertain). GLP-1 drugs (Ozempic, Mounjaro) are reducing diabetes incidence + HbA1c. Long-term: could reduce CGM TAM among well-managed type 2 patients. Short-term: may increase CGM use as part of integrated diabetes management. Bears + bulls debate this; mgmt has framed as net positive (better-managed patients = continued CGM users).
EHR integration / interoperability. 160+ health systems integrated. Requires continued investment in connectivity + data standards + payer integration. EHR vendor dynamics + data portability rules affect adoption.
Manufacturing concentration. Ireland + US manufacturing plus partner ecosystem. Scaling new sensor production + 15-day platform requires capital + execution. Manufacturing setbacks could disrupt revenue cadence.
Regulatory / FDA. New product approvals (G7 15-day, future generations) require FDA clearance. Pre-market filings + clinical evidence + commercial launch timing dependencies.
Bottom line
Dexcom FY25 is the structural margin inflection year: Q4 gross margin 63.5% (+410bp YoY), revenue $4.66B (+13%), op income +52% to $912M, EPS $2.09 (+47%), FCF $1.08B (+71%). G7 15-day broadly rolled out US; International Q4 +18% (organic 15%); France type 2 access expansion; Stelo OTC platform launched; DexCom Smart Basal + Direct EHR integration with 160+ health systems.
FY26 guide of $5.16-$5.25B revenue (+11-13%) + 63-64% gross margin (+200-300bp) + 22-23% op margin + 30-31% adj EBITDA margin = continued multi-year compounding. The structural levers (G7 15-day mix, international scaling, Stelo OTC, EHR integration, Ireland manufacturing) all in motion.
The risks are real — coverage landscape, competitive dynamics (Abbott Libre primary), supply chain, international margin, G7 15-day adoption pace, Stelo OTC dynamics, GLP-1 drug impact, EHR integration complexity, manufacturing concentration, regulatory/FDA. The bear case (GLP-1 reduces CGM TAM) is debated but mgmt frames as net positive.
But the structural thesis (CGM market expansion + G7 15-day platform + international scaling + Stelo OTC + EHR ecosystem + manufacturing scale + capital return) is intact and the FY25 print confirms. Quality medical device compounder with the cleanest structural margin expansion trajectory in CGM. Investors get exposure to the diabetes care transformation + structural margin expansion + international growth + new TAM (Stelo OTC).
Citations
- DexCom, Inc. FY25 Form 10-K (filed February 2026, SEC EDGAR).
- DXCM Q4 2025 earnings call, 2026-02-12 — FY revenue $4.66B (+13%); Q4 worldwide $1.26B (+13%); US Q4 +11%; International Q4 +18% (organic 15%); Q4 gross margin 63.5% (+410bp); G7 15-day broadly rolled out US; France type 2 access; Stelo nutrition database; DexCom Smart Basal; Direct EHR 160+ health systems; FY26 guide ($5.16-$5.25B revenue, 63-64% GM, 22-23% op margin, 30-31% adj EBITDA margin).
- DXCM Q3 2025 / Q2 2025 / Q1 2025 earnings calls — supporting G7 launch + international expansion + product roadmap (assumed in line with Q4 trajectory).
- Internal financial_statements view (consolidated annual + cash flow + capital structure).